Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors
Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
US Biodefense Market Outlook 2022: Biodefense Market to Grow at a CAGR of 9% during the Forecasted Period of 2017-2022 - Research and Markets
This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.